Non-specific Effects of Rabies Vaccine

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

546 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-08-29

Study Completion Date

2020-07-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Vaccines work by stimulating the body to produce a high-quality, rapid and specific immune response upon exposure to infection by a particular disease-causing microorganism - the microorganism targeted by the vaccine. Evidence is emerging that some vaccines may have additional 'non-specific effects' (NSEs); that is, effects on the immune system beyond the direct protection against the diseases for which the vaccines were developed. It has been proposed that rabies vaccine has protective NSEs in people and animals, with receipt of rabies vaccine in children associated with a reduced risk of meningitis and cerebral malaria in one study, and a history of rabies vaccination in free-roaming dogs associated with increased survival rates in another study. Studies in mice have shown that prior rabies vaccination protects against bacterial sepsis. The biological mechanism of action of any such NSE of rabies vaccine is unknown. Other vaccines with reported protective NSEs (e.g. bacillus Calmette-Guerin vaccine against tuberculosis, a disease caused by Mycobacterium tuberculosis) have been show to reprogram the immune system, leading to enhanced protection against infection with disease-causing microorganisms unrelated to M. tuberculosis.

In this study, we will test the hypothesis that rabies vaccine has non-specific protective effects against common infectious disease (CID) syndromes (upper respiratory illness, diarrhea and fever) in a population of veterinary students. We will randomly assign previously-unvaccinated students who volunteer for the study to receive a primary course of three injections of rabies vaccine (experimental group) or an identical course of three injections of sterile water (control group). Participants will not know to which group they have been assigned. We will ask all participants to report episodes of illness through an online survey each week for 26 weeks, and will also record all clinically- and laboratory-confirmed cases of illness with CID syndromes. We hypothesize that rates of self-reported new episodes of CID illness over 26 weeks will be at least 25% lower in the experimental group, relative to the control group.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety of Rabivax-S for Pre-exposure Prophylaxis

NCT03741270

Rabies Vaccine Adverse Reaction

COMPLETED PHASE4

Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Simulated Post-exposure Prophylaxis Regimen

NCT07055893

Rabies (Healthy Volunteers)

NOT_YET_RECRUITING PHASE3

Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Pre-exposure Prophylaxis Regimen

NCT07055295

Rabies

NOT_YET_RECRUITING PHASE3

Prevention of Rabies With Four Doses of Rabies Vaccine

NCT05545371

Rabies Human Antibody

ENROLLING_BY_INVITATION PHASE3

Immunogenicity and Safety of Different Dosages of Rabies Vaccine (Serum-free Vero Cell)

NCT07055880

Rabies

NOT_YET_RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Influenza-like Illness Upper Respiratory Disease Diarrhea Fever

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

The trial design is a single-site, two-arm, parallel-group, participant-blinded, randomized, placebo-controlled, two-sided comparative study, with an internal pilot study for blinded sample size re-estimation. Allocation to study arm will be by block randomization stratified by sex within cohort (semester) with a 1:1 allocation ratio.

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Participants

Participants will be blinded to their study arm allocation. The intervention procedure will be identical for both arms (intramuscular injections at Student Health Services on days 0, 7 and 21). Participants allocated to the control group will receive an intramuscular injection of sterile water for injection using identical syringes and needles as for the vaccine group. The injection will be prepared in a separate room to maintain participant blinding.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vaccine group

Three dose primary course of Rabivax-S. Dosing and administration of the vaccine (Rabivax-S) will be according to the package insert, following the schedule for pre-exposure prophylaxis via the intramuscular route; that is, 1 mL by intramuscular injection in the deltoid area of the arm on Day 0, Day 7 and Day 21.

Group Type EXPERIMENTAL

Rabivax-S

Intervention Type BIOLOGICAL

Rabivax-S is a lyophilized vaccine manufactured by Serum Institute of India Pvt. Ltd. containing inactivated purified rabies antigen (Pitman Moore, PM3218 as virus strain) produced using Vero ATCC CCL 81 cells. The diluent (sterile water for injection) is provided in a separate 1 mL ampoule. After reconstitution, a single dose of 1 mL contains an inactivated, purified rabies antigen (not less than 2.5 IU), glycine (40 mg), sucrose (40 mg) and human serum albumin (25% 10 mg).

Control group

The intervention (placebo) in the control group is at least one dose (1 mL by intramuscular injection) of a three dose primary course (on days 0, 7 and 21) of vaccine diluent (sterile water for injection).

Group Type PLACEBO_COMPARATOR

Sterile Water Injection

Intervention Type DRUG

The vaccine diluent (sterile water for injection) is provided in a separate 1 mL ampoule.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rabivax-S

Rabivax-S is a lyophilized vaccine manufactured by Serum Institute of India Pvt. Ltd. containing inactivated purified rabies antigen (Pitman Moore, PM3218 as virus strain) produced using Vero ATCC CCL 81 cells. The diluent (sterile water for injection) is provided in a separate 1 mL ampoule. After reconstitution, a single dose of 1 mL contains an inactivated, purified rabies antigen (not less than 2.5 IU), glycine (40 mg), sucrose (40 mg) and human serum albumin (25% 10 mg).

Intervention Type BIOLOGICAL

Sterile Water Injection

The vaccine diluent (sterile water for injection) is provided in a separate 1 mL ampoule.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

A student registered at RUSVM, and in the Veterinary Preparatory (VP) program or the 1st or 5th semester of the Doctor of Veterinary Medicine (DVM) program

Exclusion Criteria

A student registered at RUSVM and in the VP program or the 1st or 5th semester of the DVM program will be excluded from the study if s/he:

1. has previously received a dose of rabies vaccine, or
2. is intending to undertake activities during the course of participation in the study that would increase their risk category of rabies exposure above that of the U.S. population at large, as defined by the Advisory Committee on Immunization Practices (ACIP) for human rabies prevention, or
3. does not provide informed consent for participation, or
4. enrolls in the study but does not present for the first injection within the first 12 weeks of the semester (up to and including Week 12), or
5. has a contraindication to rabies vaccine as described in the Rabivax-S package insert

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes